Çirkin, G.; Aydemir, S.; Açıkgöz, B.; Çelik, A.; Güler, Y.; Kiray, M.; Baykara, B.; Dinleyici, E.Ç.; Öztürk, Y.
Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. Int. J. Mol. Sci. 2025, 26, 8616.
https://doi.org/10.3390/ijms26178616
AMA Style
Çirkin G, Aydemir S, Açıkgöz B, Çelik A, Güler Y, Kiray M, Baykara B, Dinleyici EÇ, Öztürk Y.
Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. International Journal of Molecular Sciences. 2025; 26(17):8616.
https://doi.org/10.3390/ijms26178616
Chicago/Turabian Style
Çirkin, Gül, Selma Aydemir, Burcu Açıkgöz, Aslı Çelik, Yunus Güler, Müge Kiray, Başak Baykara, Ener Çağrı Dinleyici, and Yeşim Öztürk.
2025. "Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota" International Journal of Molecular Sciences 26, no. 17: 8616.
https://doi.org/10.3390/ijms26178616
APA Style
Çirkin, G., Aydemir, S., Açıkgöz, B., Çelik, A., Güler, Y., Kiray, M., Baykara, B., Dinleyici, E. Ç., & Öztürk, Y.
(2025). Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. International Journal of Molecular Sciences, 26(17), 8616.
https://doi.org/10.3390/ijms26178616